ReviewBest practice & research. Clinical rheumatology2009
Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.
Review in Best practice & research. Clinical rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02594735 (Abatacept for the Treatment of Refractory Juvenile Dermatomyositis), which is not on this map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Abatacept for the Treatment of Refractory Juvenile Dermatomyositis
Who cites it
41 citing papers in PubMed, 122 citations in OpenAlex.
- NMJ-associated transcriptomic remodeling correlates with disease severity in juvenile dermatomyositis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Distinct by Design: Unraveling the Unique Clinical and Transcriptomic Identity of Juvenile Scleromyositis Overlap Compared to Juvenile Systemic Sclerosis and Juvenile Dermatomyositis: Implications for Care and Pathogenesis.ACR open rheumatology · 2026Article
- Idiopathic Inflammatory Myopathies: Recent Evidence Linking Pathogenesis and Clinical Features.International journal of molecular sciences · 2025Review
- Basic Investigations in Pediatric Rheumatology.Indian journal of pediatrics · 2024Review
- Contribution of Complement, Microangiopathy and Inflammation in Idiopathic Inflammatory Myopathies.Journal of neuromuscular diseases · 2024Review
- A diagnostic challenge: misdiagnosing Blau syndrome as juvenile dermatomyositis in a pediatric patient.Annals of medicine and surgery (2012) · 2023Article
- Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care.Nature reviews. Rheumatology · 2023Review
- Single-cell profiling of peripheral blood and muscle cells reveals inflammatory features of juvenile dermatomyositis.Frontiers in cell and developmental biology · 2023Article
- Update on Biomarkers of Vasculopathy in Juvenile and Adult Myositis.Current rheumatology reports · 2022Review
- JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology.Pediatric rheumatology online journal · 2021Review
- Treatment of Calcinosis in Juvenile Dermatomyositis.Current rheumatology reports · 2021Review
- Inflammatory milieu of muscle biopsies in juvenile dermatomyositis.Rheumatology international · 2021Observational
- Assessment of the Clinical Effects of Aquatic-based Exercises in the Treatment of Children With Juvenile Dermatomyositis: A 2x2 Controlled-Crossover Trial.Archives of rheumatology · 2020Article
- Being on the juvenile dermatomyositis rollercoaster: a qualitative study.Pediatric rheumatology online journal · 2019Article
- Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study.Pediatric rheumatology online journal · 2018Article
- The Vasculopathy of Juvenile Dermatomyositis.Frontiers in pediatrics · 2018Review
- Severe Recurrent Necrotizing Myopathy in Pregnancy: A Case Report.Frontiers in neurology · 2018Article
- Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.Frontiers in immunology · 2018Review
- Treatment of Juvenile Dermatomyositis: An Update.Paediatric drugs · 2017Review
- Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India.Rheumatology international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Juvenile dermatomyositis (JDM) is a rare, potentially life-threatening systemic autoimmune disease primarily affecting muscle and skin. Recent advances in the recognition, standardised assessment and treatment of JDM have been greatly facilitated by large collaborative research networks. Through these networks, a number of immunogenetic risk factors have now been defined, as well as a number of potential pathways identified in the aetio-pathogenesis of JDM. Myositis-associated and myositis-specific autoantibodies are helping to sub-phenotype JDM, defined by clinical features, outcomes and immunogenetic risk factors. Partially validated tools to assess disease activity and damage have assisted in standardising outcomes. Aggressive treatment approaches, including multiple initial therapies, as well as new drugs and biological therapies for refractory disease, offer promise of improved outcomes and less corticosteroid-related toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.